XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Total Shareholders' Equity
Total Shareholders' Equity
Leveraged Stock Units (LSUs)
Total Shareholders' Equity
Cumulative-effect adjustment from adoption of ASC 2020-06
Class A Common Stock
Class A Common Stock
Performance-Based Restricted Stock Units (PSUs)
Class A Common Stock
Leveraged Stock Units (LSUs)
Additional Paid-In Capital
Additional Paid-In Capital
Performance-Based Restricted Stock Units (PSUs)
Additional Paid-In Capital
Leveraged Stock Units (LSUs)
Additional Paid-In Capital
Cumulative-effect adjustment from adoption of ASC 2020-06
Accumulated Other Comprehensive Loss
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative-effect adjustment from adoption of ASC 2020-06
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2020 0                            
Series A preferred stock , Beginning balance at Dec. 31, 2020 $ 0                            
Series A preferred stock , Ending balance (in shares) at Dec. 31, 2021 0                            
Series A preferred stock , Ending balance at Dec. 31, 2021 $ 0                            
Beginning balance (in shares) at Dec. 31, 2020         85,895,000                    
Beginning balance at Dec. 31, 2020   $ 619,600     $ 859     $ 1,229,320       $ (278) $ (589,178)   $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense   16,711           16,711              
Exercise of stock options (in shares)         1,490,000                    
Exercise of stock options   13,289     $ 15     13,274              
Restricted stock units vested, net of shares withheld for taxes (in shares)         492,000                    
Restricted stock units vested, net of shares withheld for taxes   (3,850)     $ 5     (3,855)              
Shares issued for acquisition (in shares)         1,771,000                    
Shares issued for acquisition   56,626     $ 18     56,608              
Exchange and conversion of 2024 notes (in shares)         1,095,000                    
Exchange and conversion of 2024 notes   28,492     $ 11     28,481              
Class A common stock issued for payment of earn-outs (in shares)         16,000                    
Class A common stock issued for payment of earn-outs   450           450              
Foreign currency translation adjustment (84) (84)                   (84)      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (37,601) (37,601)                     (37,601)    
Ending balance (in shares) at Dec. 31, 2021         90,759,000                    
Ending balance at Dec. 31, 2021   693,633   $ (66,383) $ 908     1,340,989     $ (106,172) (362) (626,779) $ 39,789 (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06                            
Series A preferred stock , Ending balance (in shares) at Dec. 31, 2022 0                            
Series A preferred stock , Ending balance at Dec. 31, 2022 $ 0                            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense   33,981           33,981              
Exercise of stock options (in shares)         651,000                    
Exercise of stock options   4,452     $ 6     4,446              
Restricted stock units vested, net of shares withheld for taxes (in shares)         496,000                    
Restricted stock units vested, net of shares withheld for taxes   (7,086)     $ 5     (7,091)              
Stock units vested, net of shares withheld for taxes (in shares)         459,000                    
Stock units vested, net of shares withheld for taxes   (11,232)     $ 5     (11,237)              
Shares issued for acquisition (in shares)         3,742,000                    
Shares issued for acquisition   130,175     $ 37     130,138              
Exchange and conversion of 2024 notes (in shares)         5,394,000                    
Exchange and conversion of 2024 notes   101,857     $ 54     101,803              
Foreign currency translation adjustment (816) (816)                   (816)      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (19,164) (19,164)                     (19,164)    
Ending balance (in shares) at Dec. 31, 2022 101,500,558       101,501,000                    
Ending balance at Dec. 31, 2022 $ 859,417 859,417     $ 1,015     1,486,857       (1,178) (606,154)   (21,123)
Increase (Decrease) in Temporary Equity [Roll Forward]                              
Issuance of series A preferred stock, net of issuance costs (in shares) 175,000                            
Issuance of series A preferred stock, net of issuance costs $ 168,000                            
Net loss attributable to common shareholders of Evolent Health, Inc. $ 10,427                            
Series A preferred stock , Ending balance (in shares) at Dec. 31, 2023 175,000                            
Series A preferred stock , Ending balance at Dec. 31, 2023 $ 178,427                            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock-based compensation expense   40,501           40,501              
Exercise of stock options (in shares) 1,237,000       1,406,000                    
Exercise of stock options   12,519     $ 14     12,505              
Restricted stock units vested, net of shares withheld for taxes (in shares)         630,000                    
Restricted stock units vested, net of shares withheld for taxes   (11,317)     $ 6     (11,323)              
Stock units vested, net of shares withheld for taxes (in shares)           202,000 1,040,000                
Stock units vested, net of shares withheld for taxes $ (3,975)   $ 0     $ 2 $ 10   $ (3,977) $ (10)          
Shares issued for acquisition (in shares)         8,475,000                    
Shares issued for acquisition 261,271       $ 85     261,186              
Exchange and conversion of 2024 notes (in shares)         1,294,000                    
Exchange and conversion of 2024 notes   $ 23,073     $ 13     23,060              
Class A common stock issued for payment of earn-outs (in shares)         877,000                    
Class A common stock issued for payment of earn-outs 28,551       $ 9     28,542              
Foreign currency translation adjustment (79)                     (79)      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (142,260)             (29,220)         (113,040)    
Ending balance (in shares) at Dec. 31, 2023 115,424,833       115,425,000                    
Ending balance at Dec. 31, 2023 $ 1,067,701       $ 1,154     $ 1,808,121       $ (1,257) $ (719,194)   $ (21,123)